Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Descriptive ethics

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    23 result(s) found for: Descriptive ethics. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2013-005384-66 Sponsor Protocol Number: AUX-CC-807 Start Date*: 2014-04-28
    Sponsor Name:Endo Ventures Limited
    Full Title: A phase 3b, open-label pilot study to evaluate the safety and effectiveness of up to four treatment cycles of AA4500 in combination with the ErecAid® Esteem® Manual Vacuum Therapy System in men wit...
    Medical condition: Peyronie's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-015795-10 Sponsor Protocol Number: SMA-09-19-SVN Start Date*: 2009-11-12
    Sponsor Name:Alcon d.o.o.
    Full Title: Assessing the safety and efficacy of switching to Azarga (Brinzolamide/Timolol Fixed Combination), as replacement therapy in patients with uncontrolled intraocular pressure
    Medical condition: uncontrolled intraocular pressure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: View results
    EudraCT Number: 2018-003528-35 Sponsor Protocol Number: 2693-CL-0301 Start Date*: 2019-11-22
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: A Phase 3, Randomized, Placebo-controlled, 12-week Double-blind Study, followed by a Non-Controlled Extension Treatment Period, to Assess the Efficacy and Safety of Fezolinetant in Women Suffering ...
    Medical condition: Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated with Menopause
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004866 10020407 Hot flashes LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2020-001803-17 Sponsor Protocol Number: GS-US-540-5823 Start Date*: 2020-07-14
    Sponsor Name:Gilead Sciences Inc.
    Full Title: A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants from Birth to < 18 Years of Age with COVID-19
    Medical condition: Coronavirus disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003529-27 Sponsor Protocol Number: 2693-CL-0302 Start Date*: 2019-10-03
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: A Phase 3, Randomized, Placebo-controlled, 12-week Double-blind Study, followed by a Non- Controlled Extension Treatment Period, to Assess the Efficacy and Safety of Fezolinetant in Women Suffering...
    Medical condition: Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated with Menopause
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004866 10020407 Hot flashes LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) LV (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2004-000315-26 Sponsor Protocol Number: MO18024 Start Date*: 2004-11-25
    Sponsor Name:F.Hoffmann-La Roche Ltd.
    Full Title: First-line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum. An Expanded Access Program.
    Medical condition: Metastatic cancer of the colon or rectum.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-003701-25 Sponsor Protocol Number: 7035-CL-0014 Start Date*: 2013-12-09
    Sponsor Name:Tacurion Pharma Inc
    Full Title: A Phase II, Multicenter,Randomization, Double-Blind, Parallel Group, Placebo-Controlled, Forced Titration Proof of Concept Study to Assess Efficacy, Safety, Tolerability and the Therapeutic Ratio ...
    Medical condition: Nocturia associated with nocturnal polyuria
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10064016 Nocturnal polyuria LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PL (Completed) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001418-27 Sponsor Protocol Number: 20150168 Start Date*: 2019-01-29
    Sponsor Name:Amgen Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF ABP 959 COMPARED WITH ECULIZUMAB IN ADULT SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) NL (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) NO (Completed) SI (Completed) IE (Completed) FI (Completed) SE (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003008-38 Sponsor Protocol Number: 105MS306 Start Date*: 2019-06-17
    Sponsor Name:Biogen Idec Research Limited
    Full Title: An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years f...
    Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) FR (Completed) PT (Completed) BG (Trial now transitioned) HU (Trial now transitioned) BE (Completed) SK (Trial now transitioned) GR (Completed) DE (Completed) ES (Ongoing) HR (Trial now transitioned) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004175-22 Sponsor Protocol Number: HC-G-H-0803 Start Date*: Information not available in EudraCT
    Sponsor Name:B. Braun Melsungen AG
    Full Title: PROSPECTIVE, CONTROLLED, DOUBLE-BLIND, RANDOMIZED MULTICENTRIC STUDY ON THE EFFICACY AND SAFETY OF A TARGET CONTROLLED PLASMA VOLUME REPLACEMENT THERAPY WITH A HYPER-ONCOTIC BALANCED HES 130/0.42...
    Medical condition: Intraoperative plasma volume replacement requirement in elective surgery of the pancreatic head (pylorus preserving pancreatic-duodenectomy, PPPD)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10022891 - Investigations 10059909 Volume plasma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000368-90 Sponsor Protocol Number: 218MS205 Start Date*: 2012-08-08
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Exploratory Study to Assess the Effect of Treatment With Prolonged-Release Fampridine (BIIB041) 10 mg Twice Daily on Walking Ability and ...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002500-91 Sponsor Protocol Number: RPC01-3001 Start Date*: 2015-10-12
    Sponsor Name:Celgene International II Sàrl (CIS II)
    Full Title: A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) GB (Completed) ES (Completed) BG (Completed) SK (Completed) GR (Completed) PL (Completed) LV (Completed) EE (Completed) LT (Completed) PT (Completed) SE (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-014493-18 Sponsor Protocol Number: B1971012(6108A1-2003-EU) Start Date*: 2010-07-20
    Sponsor Name:Pfizer Inc 235 East 42nd Street, New York, NY10017
    Full Title: A Phase 2, Randomized, Placebo-Controlled, Single-blind Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Administered in Either 2- or 3-Dose Regimens in...
    Medical condition: Healthy volunteers (prevention of bacterial meningitis).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10027202 Meningitis bacterial PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) ES (Completed) PL (Completed) DE (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-023382-22 Sponsor Protocol Number: 9521-CL-0002 Start Date*: 2011-02-21
    Sponsor Name:Astellas Pharma Europe B.V. (APEB)
    Full Title: Phase I/II, multi-center, open label study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of ASP9521 in patients with metastatic castrate-resistant p...
    Medical condition: metastatic castrate-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000452-16 Sponsor Protocol Number: 156-03-244 Start Date*: 2004-08-02
    Sponsor Name:Otsuka Maryland Research Institute
    Full Title: International, Multi-Centre, Study of One year, Open Label, Titrated Oral Tolvaptan Tablet Administration in Patients with Chronic Hyponatraemia: Extension to Studies 156-02-235 and 156-03-238 to a...
    Medical condition: Ongoing hyponatraemia in euvolemic and hypervolemic states
    Disease: Version SOC Term Classification Code Term Level
    7 10021036 1.1
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004109-25 Sponsor Protocol Number: P261-402 Start Date*: 2012-05-03
    Sponsor Name:Upsher-Smith Laboratories, Inc.
    Full Title: An Open-Label Safety Study of USL261 in the Outpatient Treatment of Subjects with Seizure Clusters
    Medical condition: Epilepsy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10015052 Epileptic seizure LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002192-10 Sponsor Protocol Number: ST10-01-103 Start Date*: 2017-02-16
    Sponsor Name:Shield TX (UK) Limited
    Full Title: A phase 1, open label, randomised, repeat dose, parallel group study to evaluate the pharmacokinetics, safety and tolerability of ferric maltol at the three dosage levels in paediatric subjects age...
    Medical condition: Iron deficiency (with or without anaemia)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10022972 Iron deficiency anaemia PT
    20.0 100000012842 10002062 Anaemia iron deficiency LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-003447-11 Sponsor Protocol Number: C-145-04 Start Date*: 2017-10-27
    Sponsor Name:Iovance Biotherapeutics, Inc.
    Full Title: A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma
    Medical condition: Recurrent, metastatic, or persistent Cervical Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10008229 Cervical cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Prematurely Ended) ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-022921-13 Sponsor Protocol Number: AUX-CC-802 Start Date*: 2011-01-24
    Sponsor Name:Auxilium UK Limited
    Full Title: A PHASE 3, OPEN-LABEL STUDY OF THE SAFETY AND EFFECTIVENESS OF AA4500 ADMINISTERED TWICE PER TREATMENT CYCLE FOR UP TO FOUR TREATMENT CYCLES (2 x 4) IN MEN WITH PEYRONIE’S DISEASE
    Medical condition: Peyronie's Disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038604 - Reproductive system and breast disorders 10034765 Peyronie's disease PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) GB (Completed) DE (Completed) DK (Completed) FR (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000072-42 Sponsor Protocol Number: RG_11-087 Start Date*: 2013-02-06
    Sponsor Name:The University of Birmingham
    Full Title: A randomised phase IIb trial of bevacizumab added to temozolomide ± irinotecan for children with refractory/relapsed neuroblastoma – BEACON-Neuroblastoma Trial
    Medical condition: Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10029261 Neuroblastoma NOS LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) DK (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) IT (Completed) AT (Completed) DE (Prematurely Ended) BE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 12 00:19:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA